Erratum

Article Figures & Data

TABLE 3

Peptide Receptor Radionuclide Therapy in 58 Patients with Differentiated Thyroid Carcinoma

References	Tumor classification	Radiopharmaceutical			Cumulative dose	Response (TTP [mo])	Criteria*
References	Tumor classification	Radionuclide	Chelator	Peptide	Cumulative dose	Response (TTP [mo])	Criteria*
Gorges et al., 2001	3 × HCTC	⁹⁰Y	DOTA	TOC	1.7–9.6 GBq	1 × SD (21), 2 × PD	NA
Waldherr et al., 2001	3 × FTC; 4 × PTC; 1 × ATC	⁹⁰Y	DOTA	TOC	1.7–14.8 GBq	2 × SD (8,8); 6 × PD	WHO
Virgolini et al., 2002	25 × TC	⁹⁰Y	DOTA	Lanreotide	0.9–7.0 GBq	3 × RD (NA), 11 × SD (NA), 11 × PD	WHO
Valkema et al., 2002	1 × FTC; 4 × PTC	¹¹¹ln	DTPA	Octreotide	29.5–83.2 GBq	4 × PD; 1 × SD (NA)	SWOG
Chinol et al., 2002	2 × PTC	⁹⁰Y	DOTA	TOC	>7.4 GBq	NA	SWOG
Christian et al., 2003	1 × HCTC	⁹⁰Y	DOTA	TOC	NA	NA	NA
Gabriel et al., 2004	4 × FTC; 1 × PTC	⁹⁰Y	DOTA	TOC	5.6–7.4 GBq	5 × SD (5)	NA
Stokkel et al., 2004	4 × FTC; 5 × PTC	¹¹¹ln	DTPA	Octreotide	14.3–33.1 GBq	4 × SD; 5 × PD	NA

↵* WHO = World Health Organization criteria: regressive disease (RD) = >25% reduction in tumor size; SD = <25% reduction or increase in tumor size; PD = >25% increase in tumor size. SWOG = Southwest Oncology Group criteria of tumor response: PR = >50% reduction in tumor size; SD = ±25% reduction or increase in tumor size; PD = >25% increase in tumor size.

TC = undefined thyroid cancer; ATC = anaplastic thyroid carcinoma; NA = not available.